Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban
Clinical Cardiology · 2024
DOI: 10.1002/clc.24189 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Nicolás Manito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital Universitario de Bellvitge, Barcelona, Spain. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Thromboembolism, Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer Hispania SL.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Patients with atrial fibrillation (AF) and heart failure (HF) have a high risk of thromboembolism and other outcomes and anticoagulation is recommended. Hypothesis This study was aimed to explore the risk factors associated with HF worsening in patients with AF and HF taking rivaroxaban in Spain.
Methods
Multicenter, prospective, observational study that included adults with AF and chronic HF, receiving rivaroxaban ≥4 months before entering. HF worsening was defined as first hospitalization or emergency visit because of HF exacerbation.
Results
A total of 672 patients from 71 Spanish centers were recruited, of whom 658 (97.9%) were included in the safety analysis and 552 (82.1%) in the per protocol analysis. At baseline, mean age was 73.7 ± 10.9 years, 64.9% were male, CHA 2 DS 2 ‐VASc was 4.1 ± 1.5, HAS‐BLED was 1.6 ± 0.9% and 51.3% had HF with preserved ejection fraction. After 24 months of follow‐up, 24.9% of patients developed HF worsening, 11.6% died, 2.9% had a thromboembolic event, 3.1% a major bleeding, 0.5% an intracranial bleeding and no patient had a fatal hemorrhage. Older age, the history of chronic obstructive pulmonary disease, the previous use of vitamin K antagonists, and restrictive or infiltrative cardiomyopathies, were independently associated with HF worsening. Only 6.9% of patients permanently discontinued rivaroxaban treatment.
Conclusions
Approximately one out of four patients with HF and AF treated with rivaroxaban developed a HF worsening episode after 2 years of follow‐up. The identification of those factors that increase the risk of HF worsening could be helpful in the comprehensive management of this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Department, Hospital Universitario de Bellvitge, Barcelona, Spain.
- Department of Internal Medicine, Hospital Vega Baja, Orihuela, Spain.
- Cardiology Department, Hospital del Mar, Barcelona, Spain.
- Cardiology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
- Consulta cardiología Galve Basilio, Barcelona, Spain.
- Cardiology Department, IBSAL-Hospital Universitario de Salamanca, Universidad de Salamanca, CIBER-CV, Salamanca, Spain.
Förderung
- Bayer Hispania SL
Zitieren
APA
Manito, N., Cepeda-Rodrigo, J. M., Farré, N., Castillo Orive, M., Galve, E., Jiménez-Candil, J., García-Pinilla, J. M., López Sánchez, E. S., Rafols, C., & Gómez Doblas, J. J. (2024). Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban. Clinical Cardiology. https://doi.org/10.1002/clc.24189
Vancouver
Manito N, Cepeda-Rodrigo JM, Farré N, Castillo Orive M, Galve E, Jiménez-Candil J, et al. Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban. Clinical Cardiology. 2024. doi:10.1002/clc.24189
BibTeX
@article{Manito2024,
author = {Manito, Nicolás and Cepeda-Rodrigo, José María and Farré, Nuria and Castillo Orive, Miguel and Galve, Enrique and Jiménez-Candil, Javier and García-Pinilla, José M and López Sánchez, Eduardo Sebastián and Rafols, Carles and Gómez Doblas, Juan José},
title = {Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.24189}
}
EUVIMED